CPH:BAVA — Delivery of freeze-dried JYNNEOS smallpox vaccine planned for 2026
Dec 31, 2025, 10:00:00 PM UTC
Summary
Bavarian Nordic A/S announced the exercise of contract options valued at USD 143.6 million by the U.S. Government for the production and supply of the freeze-dried formulation of its JYNNEOS smallpox vaccine. The contract will enable the conversion of bulk vaccine and includes supplemental payments based on demonstrated shelf-life improvements. Deliveries are scheduled for 2026, supporting U.S. national health security. Bavarian Nordic's 2025 financial guidance remains unchanged, with anticipated revenues from its Public Preparedness segment still expected to be between DKK 3,000-4,000 million, bolstered by the recent contract options.
Company
Bavarian Nordic (CPH:BAVA)CPH — Health Care,
Similar Events
Expected NDA Acceptance for Anaphylm from FDA in Q2 2025
Aquestive Therapeutics, Inc. anticipates a potential acceptance of its New Drug Application (NDA) for Anaphylm™ (epinephrine) Sublingual Film by the U.S. Food and Drug Administration (FDA) in the second quarter of 2025. This follows the completion of clinical studies targeting pediatric patients aged 7 to 17 at risk of serious allergic reactions. The NDA submission aims to provide a new treatment option for those at risk of anaphylaxis, which carries significant clinical importance and market potential for the company.
NDA acceptance from FDAInitial Data Release for CT-95 Phase 1 Trial Scheduled for June 1, 2026
Context Therapeutics Inc. plans to release initial data from its Phase 1 trial of CT-95 on June 1, 2026. This follows the dosing of the first patient in the trial, which was announced on April 9, 2025. CT-95 is being evaluated for its potential therapeutic applications, marking a significant development in the company's pipeline.
Data ReleaseCompletion of VAX-24 Clinical Trial
Vaxcyte, Inc. announced the expected completion of its Phase 2 clinical trial for the VAX-24 vaccine, designed to evaluate its safety, tolerability, and immunogenicity in healthy infants. The trial, active since March 29, 2023, comprises 802 participants receiving four injections at different doses, with the final cohort expected to complete by December 1, 2025. VAX-24 is a 24-valent pneumococcal conjugate vaccine intended to provide enhanced protection against pneumococcal diseases in young children, complementing routine vaccinations.
clinical trial completionExpected Completion of Yellow Fever Vaccine Clinical Trial
Sanofi Pasteur, a company of Sanofi, is expected to complete a clinical trial on an investigational yellow fever vaccine by June 29, 2028. This trial compares the new vaccine with YF-VAX, the current standard, and involves 567 adult participants across the United States. The study is currently active but not recruiting new participants. The trial is in Phase 2 and aims to assess the vaccine's effectiveness over an approximate duration of 5 years. Positive results could have implications for vaccine development and public health regarding yellow fever prevention.
Clinical Trial Completion